Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 5Phase 3 4Phase 1/2 3

Status

Completed 66Terminated 12Withdrawn 6Recruiting 6Active not recruiting 5Unknown 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Brain Neoplasms 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Sirolimus × Clear all
NCT05088356 2026-05-12

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1 Active not recruiting
66 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01375829 2026-04-13

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled

Adult Solid Neoplasm

NCT02389309 2026-03-09

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
14 enrolled
CNS

Brain Neoplasms

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
249 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡